PVT1 and melanoma: Compared to those in nonmelanoma controls, the serum levels of lncRNA PVT1 in melanoma patients are significantly higher; this marker has a sensitivity of 94.12%, a specificity of 85.11%, and an area under the ROC curve (AUC) of 0.9387 for distinguishing between patients with melanoma and controls; this finding suggests that serum lncRNA PVT1 may be a new biomarker for the early diagnosis of melanoma [76].